Methotrexat Al (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing tetrahydrofolate levels needed for purine and pyrimidine synthesis. This limits DNA, RNA and protein production, thereby suppressing rapidly dividing cells such as activated immune cells in arthritis and malignant cells in cancer.

The dose of Methotrexat Al is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment goals. Only a qualified health‑care professional should determine the appropriate dosage regimen.

Methotrexate is classified as pregnancy category X because it is teratogenic and can cause fetal malformations or loss. It is contraindicated during pregnancy and women of child‑bearing potential must use effective contraception. Breastfeeding is also discouraged as the drug is excreted in milk.

To order Methotrexat Al, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Methotrexate is a cornerstone antimetabolite used when disease‑modifying antirheumatic drugs (DMARDs) such as sulfasalazine or leflunomide are insufficient, and it is often preferred over biologics for cost‑effectiveness. In oncology, it offers a distinct mechanism compared with alkylating agents, but may be combined with other chemotherapeutics for synergistic effect.

Methotrexat Al should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations. Do not freeze the solution and keep it out of reach of children.

Methotrexat Al is supplied as an injectable preparation for intramuscular or subcutaneous injection. Administration technique, injection site rotation and dosing frequency are determined by the treating physician, who will also provide guidance on pre‑medication and monitoring protocols.

The most serious adverse events include severe hepatotoxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression, acute renal failure, and severe cutaneous reactions such as Stevens‑Johnson syndrome. Prompt recognition of symptoms and regular laboratory monitoring are essential to mitigate these risks.

Methotrexat Al is contraindicated in pregnant or breastfeeding individuals, patients with severe hepatic impairment, uncontrolled infections, known hypersensitivity to methotrexate, and those with significant renal dysfunction that cannot be corrected. Caution is also advised for patients with pre‑existing lung disease.